Intellia Therapeutics, Inc.NTLANASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank73
3Y CAGR-2.5%
5Y CAGR+20.9%
Year-over-Year Change
Research and development spending
3Y CAGR
-2.5%/yr
vs +47.3%/yr prior
5Y CAGR
+20.9%/yr
Recent deceleration
Acceleration
-49.9pp
Decelerating
Percentile
P73
Within normal range
vs 5Y Ago
2.6x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $388.86M | -16.6% |
| 2024 | $466.31M | +7.2% |
| 2023 | $435.07M | +3.6% |
| 2022 | $419.98M | +82.8% |
| 2021 | $229.81M | +52.8% |
| 2020 | $150.41M | +38.7% |
| 2019 | $108.41M | +21.7% |
| 2018 | $89.11M | +31.7% |
| 2017 | $67.65M | +112.5% |
| 2016 | $31.84M | - |